Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$26.76
-2.8%		$27.57
$19.69
▼
$30.96
$4.74B0.861.35 million shs1.11 million shs
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
C$15.76
-2.1%		C$14.93
C$7.70
▼
C$17.25
N/AN/A1,770 shs400 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-1.11%-1.78%-2.55%+31.42%+16.56%
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
0.00%0.00%-5.29%+89.86%+18.47%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$26.76
-2.8%		$27.57
$19.69
▼
$30.96
$4.74B0.861.35 million shs1.11 million shs
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
C$15.76
-2.1%		C$14.93
C$7.70
▼
C$17.25
N/AN/A1,770 shs400 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-1.11%-1.78%-2.55%+31.42%+16.56%
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
0.00%0.00%-5.29%+89.86%+18.47%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.78
Moderate Buy$34.3628.40% Upside
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ACAD and NURPF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/25/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$37.00 ➝ $38.00
8/25/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$27.00 ➝ $28.00
8/25/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$39.00 ➝ $40.00
8/17/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $49.00
8/12/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
8/12/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$38.00 ➝ $41.00
8/10/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$27.00
8/10/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$35.00 ➝ $39.00
8/6/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/5/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$36.00 ➝ $37.00
(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$1.07B4.30$0.86 per share31.02$7.25 per share3.69
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$391M$2.2212.0527.31N/A33.42%9.03%6.79%11/4/2026 (Estimated)
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
N/A-C$0.01N/AN/AN/AN/AN/AN/AN/A

Latest ACAD and NURPF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.0682$0.18+$0.1119$0.18$296.55 million$308.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
3.39
3.30
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
1.74%

Insider Ownership

CompanyInsider Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
26.20%
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
798172.31 million127.16 millionOptionable
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
N/AN/AN/ANot Optionable

Recent News About These Companies

Neuren Highlights Neurodevelopment Focus and Development Risks
September 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neuren-highlights-neurodevelopment-focus-and-development-risks?utm_source=marketbeat.com&utm_medium=referral
Neuren Pharmaceuticals Earnings Call Signals Cash-Fueled Growth
August 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neuren-pharmaceuticals-earnings-call-signals-cash-fueled-growth?utm_source=marketbeat.com&utm_medium=referral
Neuren Pharmaceuticals Limited (NURPF) Q2 2026 Earnings Call Transcript
August 26, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4940247-neuren-pharmaceuticals-limited-nurpf-q2-2026-earnings-call-transcript
Neuren Pharmaceuticals Declares Interim Dividend for June 2026 Half
August 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neuren-pharmaceuticals-declares-interim-dividend-for-june-2026-half?utm_source=marketbeat.com&utm_medium=referral
Neuren launches first dividend as DAYBUE royalties and rare-disease pipeline gather pace
August 25, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neuren-launches-first-dividend-as-daybue-royalties-and-rare-disease-pipeline-gather-pace?utm_source=marketbeat.com&utm_medium=referral
Neuren Pharmaceuticals wins final European commercial approval for Daybu
August 24, 2026  |  capitalbrief.comC
Neuren Set for European Windfall as Rett Drug DAYBU Wins EU Approval
August 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neuren-set-for-european-windfall-as-rett-drug-daybu-wins-eu-approval?utm_source=marketbeat.com&utm_medium=referral
Neuren to Brief Investors on H1 2026 Results as Rare Neurology Pipeline Advances
August 21, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neuren-to-brief-investors-on-h1-2026-results-as-rare-neurology-pipeline-advances?utm_source=marketbeat.com&utm_medium=referral
Neuren Pharmaceuticals Ltd NURPF
August 13, 2026  |  morningstar.comM
Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%?
August 6, 2026  |  fool.com.auhttps://www.fool.com.au/2026/08/06/are-neuren-pharmaceuticals-shares-a-buy-hold-or-sell-after-rocketing-16/
Neuren Pharma Shares Jump 16% to Lead ASX 200: The Latest
August 5, 2026  |  thebull.com.auT
Neuren Pharmaceuticals posts 30% sales jump for Daybue in Q2
August 4, 2026  |  capitalbrief.comC
Neuren Pharmaceuticals Reports Record Q2 DAYBUE Sales, Upgrades Full-Year Royalty Forecast
August 4, 2026  |  sharecafe.com.auS
Neuren lifts royalty outlook as DAYBUE sales hit record and global rollout advances
August 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neuren-lifts-royalty-outlook-as-daybue-sales-hit-record-and-global-rollout-advances?utm_source=marketbeat.com&utm_medium=referral
Neuren deepens rare disease push as Phase 3 PMS trial gains momentum
July 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neuren-deepens-rare-disease-push-as-phase-3-pms-trial-gains-momentum?utm_source=marketbeat.com&utm_medium=referral
Neuren Pharmaceuticals shares rocket after inching closer to EU approval
June 30, 2026  |  msn.comhttps://www.msn.com/en-au/money/general/neuren-pharmaceuticals-shares-rocket-after-inching-closer-to-eu-approval/ar-AA26PsXn
Neuren launches Investor Hub to bolster engagement as neurological pipeline advances
June 29, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NURPF/pressreleases/1893874/neuren-launches-investor-hub-to-bolster-engagement-as-neurological-pipeline-advances/
Neuren Set for Major EU Milestone as EMA Backs DAYBU for Rett Syndrome
June 28, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neuren-set-for-major-eu-milestone-as-ema-backs-daybu-for-rett-syndrome?utm_source=marketbeat.com&utm_medium=referral
NURPF Neuren Pharmaceuticals Limited
June 17, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/NURPF
Neuren Issues 360,000 Unquoted Shares Under Employee Incentive Scheme
June 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neuren-issues-360000-unquoted-shares-under-employee-incentive-scheme?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$26.76 -0.76 (-2.76%)
Closing price 04:00 PM Eastern
Extended Trading
$26.76 0.00 (0.00%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Neuren Pharmaceuticals stock logo

Neuren Pharmaceuticals OTCMKTS:NURPF

C$15.76 -0.34 (-2.11%)
As of 01:50 PM Eastern

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas